Introducing our new Chemiluminescence Immunoassay (CLIA) kit, designed to provide accurate and rapid detection of various biomarkers and analytes in biological samples. Our CLIA technology offers a highly sensitive and specific method for immunoassay testing, making it ideal for research, clinical diagnostics, and drug development applications. The Chemiluminescence Immunoassay kit utilizes a unique combination of chemiluminescent signals and antibody-antigen interactions to enable the detection and quantification of target molecules. This results in a highly sensitive and reliable assay with a wide dynamic range, allowing for the precise measurement of analytes at low concentrations. Our CLIA kit is easy to use, with a simple and streamlined assay protocol that minimizes hands-on time and maximizes efficiency. It is compatible with a range of sample types, including serum, plasma, urine, and cell culture supernatants, providing flexibility for different research and diagnostic needs. With its high performance and user-friendly design, our Chemiluminescence Immunoassay kit is a valuable tool for researchers and clinicians looking to accurately measure biomarkers and analytes in a wide variety of sample types. Whether you are studying protein biomarkers, infectious diseases, or autoimmune conditions, our CLIA kit offers a reliable and convenient solution for your immunoassay testing needs.

Beijing, China - In a groundbreaking development, researchers at Beijing Beier Bioengineering Co., Ltd. have announced a major breakthrough in the fight against Treponema Pallidum, the bacterium that

Beijing Beier Bioengineering Co., Ltd., a high-tech enterprise in China specializing in the development and production of in vitro diagnostic reagents, has recently introduced a new Rtk Antigen Self T